Pharmaceuticals 2011, 4(8), 1070-1087; doi:10.3390/ph4081070
Review

The Phosphatidylinositol 3-Kinase/mTor Pathway as a Therapeutic Target for Brain Aging and Neurodegeneration

David Heras-Sandovalemail, Evangelina Avila-Muñozemail and Clorinda Arias* email
Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, 04510, México D.F., Mexico
* Author to whom correspondence should be addressed.
Received: 12 May 2011; in revised form: 22 July 2011 / Accepted: 28 July 2011 / Published: 4 August 2011
(This article belongs to the Special Issue PI3 Kinase Inhibitors)
PDF Full-text Download PDF Full-Text [550 KB, uploaded 4 August 2011 18:25 CEST]
Abstract: Many pathological conditions are associated with phosphatidylinositol 3-kinase (PI3K) dysfunction, providing an incentive for the study of the effects of PI3K modulation in different aspects of diabetes, cancer, and aging. The PI3K/AKT/mTOR pathway is a key transducer of brain metabolic and mitogenic signals involved in neuronal proliferation, differentiation, and survival. In several models of neurodegenerative diseases associated with aging, the PI3K/AKT pathway has been found to be dysregulated, suggesting that two or more initiating events may trigger disease formation in an age-related manner. The search for chemical compounds able to modulate the activity of the PI3K/AKT/mTOR pathway is emerging as a potential therapeutic strategy for the treatment and/or prevention of some metabolic defects associated with brain aging. In the current review, we summarize some of the critical actions of PI3K in brain function as well as the evidence of its involvement in aging and Alzheimer’s disease.
Keywords: PI3K; mTOR; insulin resistance; brain aging; Alzheimer’s disease

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

Heras-Sandoval, D.; Avila-Muñoz, E.; Arias, C. The Phosphatidylinositol 3-Kinase/mTor Pathway as a Therapeutic Target for Brain Aging and Neurodegeneration. Pharmaceuticals 2011, 4, 1070-1087.

AMA Style

Heras-Sandoval D, Avila-Muñoz E, Arias C. The Phosphatidylinositol 3-Kinase/mTor Pathway as a Therapeutic Target for Brain Aging and Neurodegeneration. Pharmaceuticals. 2011; 4(8):1070-1087.

Chicago/Turabian Style

Heras-Sandoval, David; Avila-Muñoz, Evangelina; Arias, Clorinda. 2011. "The Phosphatidylinositol 3-Kinase/mTor Pathway as a Therapeutic Target for Brain Aging and Neurodegeneration." Pharmaceuticals 4, no. 8: 1070-1087.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert